ZIOPHARM Oncology Inc (ZIOP): Price and Financial Metrics

ZIOPHARM Oncology Inc (ZIOP): $0.87

0.01 (-0.88%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add ZIOP to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#348 of 455

in industry

ZIOP Price/Volume Stats

Current price $0.87 52-week high $5.95
Prev. close $0.87 52-week low $0.77
Day low $0.86 Volume 2,127,500
Day high $0.97 Avg. volume 2,008,312
50-day MA $1.17 Dividend yield N/A
200-day MA $2.04 Market Cap 187.12M

ZIOP Stock Price Chart Interactive Chart >


ZIOPHARM Oncology Inc (ZIOP) Company Bio


Ziopharm Oncology is a biotechnology corporation employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell-based therapies for the treatment of cancer. The company was founded in 2003 and is based in Boston, Massachusetts.


ZIOP Latest News Stream


Event/Time News Detail
Loading, please wait...

ZIOP Latest Social Stream


Loading social stream, please wait...

View Full ZIOP Social Stream

Latest ZIOP News From Around the Web

Below are the latest news stories about Ziopharm Oncology Inc that investors may wish to consider to help them evaluate ZIOP as an investment opportunity.

Ziopharm Oncology Highlights Operational Progress & Rebrands to Alaunos Therapeutics

Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patientsIn-house cGMP manufacturing facility is operational to support internal clinical development programsCompany changes name to Alaunos Therapeutics reflecting renewed

Yahoo | January 26, 2022

Allred Capital Management, LLC Buys Tractor Supply Co, Equifax Inc, NextEra Energy Inc, Sells ...

Investment company Allred Capital Management, LLC (Current Portfolio) buys Tractor Supply Co, Equifax Inc, NextEra Energy Inc, Newmont Corp, Paychex Inc, sells iShares S&P 500 Growth ETF, Vanguard Total Bond Market ETF, Ford Motor Co, Adobe Inc, AT&T Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Allred Capital Management, LLC.

Yahoo | January 25, 2022

Is ZIOPHARM Oncology (NASDAQ:ZIOP) Weighed On By Its Debt Load?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | January 21, 2022

Why Ziopharm Oncology Shares Rose 10.5% on Wednesday

The clinical-stage biopharmaceutical company is examining non-viral T-cell receptor therapies (TCR-T) to fight cancer. There are two reasons for Ziopharm's climb. First, it's a reaction to hitting its 52-week low as investors saw a potential bargain.

Yahoo | January 19, 2022

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Expected to Post Earnings of -$0.09 Per Share

Equities analysts expect ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) to report earnings of ($0.09) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for ZIOPHARM Oncologys earnings. The highest EPS estimate is ($0.07) and the lowest is ($0.11). ZIOPHARM Oncology reported earnings of ($0.11) per share during the same []

Dakota Financial News | December 19, 2021

Read More 'ZIOP' Stories Here

ZIOP Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year -74.18%
5-year -77.40%
YTD N/A
2023 N/A
2022 0.00%
2021 -56.75%
2020 -46.61%
2019 152.41%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!